Efficacy of Mindfulness Meditation on Patients With Stroke With Concurrent Coronary Heart Disease: A Randomised Controlled Trial.
Lulu Kou, Min Liu, Shaowei Kang, Guangxiao Ni
Clinical psychology & psychotherapy January 1, 2024 DOI: 10.1002/cpp.70012 via PubMed
Summary
AI-generated from the abstractAdding mindfulness meditation to standard care plus a sleep medication improved sleep quality, reduced anxiety and depression, and enhanced motor function more than standard care alone in people who had a stroke and also have coronary heart disease. In a 6-week program, those who practiced mindfulness showed better scores on measures of sleep, mood, and movement at both 6 and 12 weeks. The improvement in overall sleep quality was notably larger in the mindfulness group. The findings suggest mindfulness meditation is a helpful addition for managing sleep and emotional difficulties and supporting physical recovery after stroke in patients with heart disease.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 72 |
| Population | Patients with stroke with concurrent coronary heart disease |
| Interventions | Mindfulness meditation Eszopiclone |
| Dose | 3 mg once daily |
| Duration | 6-week intervention, 12-week follow-up |
| Keywords | Coronary heart disease Mindfulness meditation Negative emotions Sleep quality Stroke |
| Citations | 5 |
| Key finding | Mindfulness meditation plus standard care and eszopiclone improved sleep quality, reduced anxiety and depression, and improved motor function more than standard care and eszopiclone alone in patients with stroke and coronary heart disease. |
Abstract
This study aimed to investigate the efficacy of mindfulness meditation on sleep quality and negative emotions in patients with stroke with concurrent coronary heart disease. This study was a randomised controlled trial. A total of 72 patients with stroke with concurrent coronary heart disease were randomly divided into an observation group and a control group, with 36 patients in each group. The control group received routine treatment plus eszopiclone tablets at a dosage of 3 mg once daily. The observation group received mindfulness meditation in addition to the treatment given to the control group. The Pittsburgh Sleep Quality Index was used to assess sleep status, the Self-Rating Anxiety Scale and Self-Rating Depression Scale were used to assess depression and anxiety, and the Fugl-Meyer Assessment was used to assess motor function. All participants in both groups received a 6-week intervention. Pairwise comparisons revealed that the observation group had better outcomes in sleep quality, sleep onset latency, sleep duration, sleep efficiency, sleep disturbances, daytime function and total scores at both 6 and 12 weeks compared with the control group (p < 0.05). After 12 weeks of intervention, compared with the control group, the total score of sleep quality improved more significantly (9.22 ± 2.35/6.26 ± 2.47). Additionally, different treatment methods had varying effects on anxiety scores, depression scores and motor function scores between the two groups (p < 0.001). Further comparisons showed that the observation group had lower anxiety and depression scores and higher motor function scores at both 6 and 12 weeks compared with the control group (p < 0.05). Mindfulness meditation can effectively improve sleep quality and reduce negative emotions in patients with stroke with concurrent coronary heart disease, as well as promote the recovery of limb functions.